Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Genetic alterations associated with high telomeric content in sarcoma

Radwa Sharaf • 10 Sep 2022
ESMO 2022
Sarcoma

Radwa Sharaf, PhD, Foundation Medicine Inc, Cambridge, MA, discusses the results of an investigation of genetic alterations associated with high telomeric content in sarcoma. RAD51B and GID4 found to be implicated in telomeric lengthening in sarcoma and may represent research opportunities for agents aimed at targeting this pathway. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Radwa Sharaf

0:45
Are mutations in TERC template sequence reflected in telomeric repeats?
Radwa Sharaf • 9 Sep 2022
1:04
Genetic mutations associated with high telomeric content in sarcoma
Radwa Sharaf • 9 Sep 2022
0:45
The role of TERC template mutations in telomere lengthening in tumors
Radwa Sharaf • 9 Sep 2022

Related Videos

0:51
Enhanced NK-cells in stage 4 sarcoma treatment
Vaishali Kumar • 8 Apr 2024
1:12
Predictive biomarkers for checkpoint inhibitors in sarcomas
Nadia Omelchenko • 8 Apr 2024
1:26
SAINT and LINNOVATE: combining ICIs and chemotherapy in advanced STC
Nadia Omelchenko • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals